{"title": "Selecta Biosciences Receives $3 Million from NIH/NIDA to Develop Nicotine Vaccine for Smoking Cessation", "author": null, "url": "https://www.fiercebiotech.com/biotech/selecta-biosciences-receives-3-million-from-nih-nida-to-develop-nicotine-vaccine-for", "hostname": "fiercebiotech.com", "description": "-- Targeted Synthetic Vaccine Particles (tSVP) Offer Potential for Increased Anti-Nicotine Efficacy to Increase Success of Smoking Cessation -- WATERTOWN, Mass.--(BUSINESS WIRE)-- Selecta | -- Targeted Synthetic Vaccine Particles (tSVP) Offer Potential for Increased Anti-Nicotine Efficacy to Increase Success of Smoking Cessation -- WATERTOWN, Mass.--(BUSINESS WIRE)-- Selecta", "sitename": "FierceBiotech", "date": "2010-08-16", "cleaned_text": "Fierce Pharma Fierce Biotech Fierce Healthcare Fierce Life Sciences Events Advertise About Us Biotech Cell & Gene Therapy Clinical Data Venture Capital Deals Research Medtech Devices Diagnostics AI and Machine Learning CRO Special Reports Fierce 50 Resources Fierce Events Industry Events Webinars Podcasts Whitepapers Survey Events Subscribe Subscribe Biotech Cell & Gene Therapy Clinical Data Venture Capital Deals Research Medtech Devices Diagnostics AI and Machine Learning CRO Special Reports Fierce 50 Resources Fierce Events Industry Events Webinars Podcasts Whitepapers Survey Events Subscribe Fierce Pharma Fierce Biotech Fierce Healthcare Fierce Life Sciences Events Advertise About Us "}